EGFR and neoplasm: CAF-mediated non-cell-autonomous adaptive resistance to MET- and EGFR-targeted therapies in lung cancers via a metabolic shift involving paracrine crosstalk between tumor cells under drug exposure and their surrounding CAFs has been reported [66].